EXEL

SEC source: 0000939767-20-000131 · wf-form4_160090636260752.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,571

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.91 to $26.49. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000131 · wf-form4_160090636260752.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,251

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 74,863 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000141 · wf-form4_160375754622244.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 931,635

F1 · shares: Represents shares of Exelixis, Inc. common stock that the Reporting Person donated as a gift to a donor advised fund.

SEC source: 0000939767-20-000141 · wf-form4_160375754622244.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 964,135

F1 · shares: Represents shares of Exelixis, Inc. common stock that the Reporting Person donated as a gift to a donor advised fund.

SEC source: 0000939767-20-000130 · wf-form4_160030226619984.xml · derivative · entry 4

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 20,000 shares

Expires 2021-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 230,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 10, 2018.

SEC source: 0000939767-20-000130 · wf-form4_160030226619984.xml · nonDerivative · entry 2

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,026

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.42. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000130 · wf-form4_160030226619984.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,026

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000141 · wf-form4_160375754622244.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 989,135

F1 · shares: Represents shares of Exelixis, Inc. common stock that the Reporting Person donated as a gift to a donor advised fund.

F2 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000129 · wf-form4_160021461881803.xml · derivative · entry 4

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 20,000 shares

Expires 2022-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, became fully exercisable on July 15, 2019.

SEC source: 0000939767-20-000129 · wf-form4_160021461881803.xml · nonDerivative · entry 2

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,882

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020.

SEC source: 0000939767-20-000129 · wf-form4_160021461881803.xml · nonDerivative · entry 1

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,882

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 54,117 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · derivative · entry 6

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 190,000 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Common Stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · derivative · entry 5

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 59,692 shares

Expires 2022-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Common Stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · nonDerivative · entry 3

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,026

F2 · kind: Represents a "net exercise" of outstanding stock options. The Reporting Person received 89,026 shares of Common Stock on the net exercise of stock options to purchase 249,692 shares of Common Stock. The Issuer withheld 160,666 shares of Common Stock underlying the stock options for payment of the exercise prices and tax withholdings using a stock price on September 8, 2020 of $20.71.

SEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · nonDerivative · entry 2

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 503,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000128 · wf-form4_159978475973402.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 313,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000127 · wf-form4_159925926667797.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,578

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.

SEC source: 0000939767-20-000127 · wf-form4_159925926667797.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,901

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 9,370 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 48,742 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000126 · wf-form4_159925919476949.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,571

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.

SEC source: 0000939767-20-000126 · wf-form4_159925919476949.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,687

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 4,498 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 74,863 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000125 · wf-form4_159925911942541.xml · nonDerivative · entry 2

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,000

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.

SEC source: 0000939767-20-000125 · wf-form4_159925911942541.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,311

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 4,998 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000124 · wf-form4_159925894699524.xml · nonDerivative · entry 2

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,882

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.

SEC source: 0000939767-20-000124 · wf-form4_159925894699524.xml · nonDerivative · entry 1

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,448

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 9,745 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 54,117 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000123 · wf-form4_159925876404670.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,191

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.

SEC source: 0000939767-20-000123 · wf-form4_159925876404670.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,708

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 9,745 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 60,367 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000122 · wf-form4_159925867553154.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,105

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.

SEC source: 0000939767-20-000122 · wf-form4_159925867553154.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,223

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 23,238 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 97,604 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000121 · wf-form4_159917791684326.xml · derivative · entry 2

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 115,396 shares

Expires 2020-12-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option, representing the right to purchase a total of 115,396 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013.

SEC source: 0000939767-20-000121 · wf-form4_159917791684326.xml · nonDerivative · entry 1

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000120 · wf-form4_159744901922438.xml · derivative · entry 2

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,662 shares

Expires 2020-12-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 59,662 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013.

SEC source: 0000939767-20-000120 · wf-form4_159744901922438.xml · nonDerivative · entry 1

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · nonDerivative · entry 6

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,031,635

F5 · kind: On July 22, 2020, the Reporting Person gifted 35,863 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · nonDerivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,985

F5 · kind: On July 22, 2020, the Reporting Person gifted 35,863 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · derivative · entry 8

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Common Stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · nonDerivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,848

F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 35,863 shares of Common Stock on the net exercise of a stock option to purchase 100,000 shares of Common Stock. The Issuer withheld 64,137 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on July 20, 2020 of $25.60.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000106 · wf-form4_159545890192637.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,189

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.89 to $25.60. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 72,614 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 995,772

F1 · kind: On July 14, 2020, the Reporting Person gifted 35,559 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000107 · wf-form4_159545916437063.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,985

F1 · kind: On July 14, 2020, the Reporting Person gifted 35,559 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000105 · wf-form4_159442849992411.xml · derivative · entry 6

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Common Stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-20-000105 · wf-form4_159442849992411.xml · nonDerivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,544

F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 35,559 shares of Common Stock on the net exercise of a stock option to purchase 100,000 shares of Common Stock. The Issuer withheld 64,441 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on July 10, 2020 of $24.94.

SEC source: 0000939767-20-000105 · wf-form4_159442849992411.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000105 · wf-form4_159442849992411.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 960,213

F1 · kind: On June 24, 2020, the Reporting Person gifted 35,189 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000105 · wf-form4_159442849992411.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,985

F1 · kind: On June 24, 2020, the Reporting Person gifted 35,189 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. Common Ctock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000104 · wf-form4_159261599241441.xml · derivative · entry 6

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 100,000 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-20-000104 · wf-form4_159261599241441.xml · nonDerivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,174

F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 35,189 shares of Common Stock on the net exercise of a stock option to purchase 100,000 shares of Common Stock. The Issuer withheld 64,811 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on June 19, 2020 of $24.18.

SEC source: 0000939767-20-000104 · wf-form4_159261599241441.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000103 · wf-form4_159183476554219.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,000 shares

Expires 2020-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 126,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017.

SEC source: 0000939767-20-000103 · wf-form4_159183476554219.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,531

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2020.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.28 to $22.81. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.